Vensica Medical, a urology therapeutics company, has secured $11 million in funding to advance its needle-free botulinum toxin A (Xeomin®) treatment for overactive bladder (OAB). This funding will support Phase 2 clinical trials across the US and Europe, aiming to provide a less invasive and more comfortable treatment option compared to traditional injections.